Compiled 2026-09-26Data through 2025-12-312 min read
Dated source-based research · No live market data

Executive summary

Annual revenue of not available and net income of USD 13.967 billion for the period ended 2025-12-31. This is a structured data brief from filed financial statements, not an independently audited investment opinion.

Business and industry context

NOVARTIS AG is an SEC-reporting issuer listed on NYSE under NVS. Its SEC industry description is Pharmaceutical Preparations. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications. Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Financial evidence

The selected fiscal period runs from 2025-01-01 to 2025-12-31. Revenue was not available; operating income was USD 17.644 billion; diluted EPS was USD 7.15 per share. Prior-period revenue was not available. The reported revenue change was not available. Comparisons are not adjusted for acquisitions, disposals, foreign exchange or fiscal-week differences.

Profitability and cash generation

Net margin, calculated as net income divided by revenue, was not available. Operating cash flow was USD 19.144 billion; capital expenditure was not available. Free cash flow (operating cash flow less purchases of property, plant and equipment) was not available. Missing standard tags are not interpreted as zero. These measures may not be directly comparable between business models.

Balance-sheet context

Total assets were USD 110.949 billion, total liabilities USD 64.400 billion and reported shareholder equity USD 46.130 billion at the period end. Total liabilities include operating obligations and are not a measure of interest-bearing debt.

Valuation context

This release does not include a synchronized market-price dataset. Consequently, price-based multiples are not quoted. P/E requires a dated share price and a clearly identified EPS basis; P/S and P/B require consistently dated capitalization and accounting denominators. A multiple alone does not establish fair value.

Risks and uncertainties

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration. Standardized XBRL can omit custom-tag disclosures. Annual data cannot establish the direction of the latest quarter.

What to monitor

Product concentration, research investment, utilization, reimbursement and cash generation. Read subsequent quarterly filings, footnotes and accounting-policy changes before interpreting these historical observations.

Methodology note

Source snapshots were collected on September 18, 2026. Values preserve reported currency and periods. This brief was compiled on September 26, 2026; the publication date is not a new source retrieval date.

Sources & dates